Long-term survival analysis of masitinib in amyotrophic lateral sclerosis.

Ther Adv Neurol Disord · 2021 · PMC8388186 · PMID 34457038

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.060so close (0.05 < p ≤ 0.1)

‘M4.5 with ⩾2 on each baseline ALSFRS-R item and ΔFS < 1.1’), ∆ALSFRS-R for masitinib was −6.36 versus −11.03 for placebo, corresponding to a significant 42% slowing in rate of decline ( p = 0.018), while PFS for this cohort showed a trend improvement of 13 months in favor of masitinib ( p = 0.060).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.